keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/27913894/use-and-effectiveness-of-tocilizumab-among-patients-with-rheumatoid-arthritis-an-observational-study-from-the-british-society-for-rheumatology-biologics-register-for-rheumatoid-arthritis
#1
Mari Kihara, Rebecca Davies, Lianne Kearsley-Fleet, Kath D Watson, Mark Lunt, Deborah P M Symmons, Kimme L Hyrich
The aims of the present study are to describe the characteristics of rheumatoid arthritis (RA) patients selected for tocilizumab (TCZ), compare the "real-world" effectiveness of TCZ and tumour necrosis factor inhibitors (TNFi) when used as a first biologic and assess the influence of past biologic exposure/concurrent methotrexate (MTX) therapy on post-TCZ treatment outcomes. The British Society for Rheumatology Biologics Register (BSRBR-RA) is a prospective cohort study following RA patients starting biologics in the UK...
December 2, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27911913/effect-of-osteoprotegerin-and-dickkopf-related-protein-1-on-radiological-progression-in-tightly-controlled-rheumatoid-arthritis
#2
Carmen Gómez-Vaquero, Irene Martín, Estibaliz Loza, Loreto Carmona, José Ivorra, José Antonio Narváez, Javier Hernández-Gañán, Pedro Alía, Javier Narváez
OBJECTIVE: To analyze the association between circulating osteoprotegerin (OPG) and Dickkopf-related protein 1 (DKK-1) and radiological progression in patients with tightly controlled rheumatoid arthritis (RA). METHODS: Serum levels of OPG and DKK-1 were measured in 97 RA patients who were treated according to a treat-to-target strategy (T2T) aimed at remission (DAS28<2.6). Radiologic joint damage progression was assessed by changes in the total Sharp-van der Heijde score (SHS) on serial radiographs of the hands and feet...
2016: PloS One
https://www.readbyqxmd.com/read/27910962/baricitinib-jak-inhibition-for-rheumatoid-arthritis
#3
J Gras
Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease characterized by inflammation and joint destruction, is associated with pain, progressive disability, systemic comorbidities and early death. Conventional disease-modifying antirheumatic drugs (DMARDs) and biological DMARDs (bDMARDs) have been able to achieve remission or a very low disease activity status for RA. Nevertheless, since many patients do not reach a sufficient response with DMARDs or present with unacceptable side effects, new therapies are needed...
October 2016: Drugs of Today
https://www.readbyqxmd.com/read/27909083/continual-maintenance-of-remission-defined-by-the-acr-eular-criteria-in-daily-practice-leads-to-better-functional-outcomes-in-patients-with-rheumatoid-arthritis
#4
Kumi Shidara, Ayako Nakajima, Eisuke Inoue, Daisuke Hoshi, Naoki Sugimoto, Yohei Seto, Eiichi Tanaka, Shigeki Momohara, Atsuo Taniguchi, Hisashi Yamanaka
OBJECTIVE: To evaluate longterm functional outcomes in rheumatoid arthritis (RA) based on the number of times that the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) or the 28-joint Disease Activity Score (DAS28) remission criteria were fulfilled. METHODS: Patients with RA who participated in all 6 data collections in an observational cohort from 2008 to 2010 and who fulfilled the DAS28 remission criteria at baseline were studied...
December 1, 2016: Journal of Rheumatology
https://www.readbyqxmd.com/read/27907269/remission-rates-with-tofacitinib-treatment-in-rheumatoid-arthritis-a-comparison-of-various-remission-criteria
#5
Josef S Smolen, Daniel Aletaha, David Gruben, Samuel H Zwillich, Sriram Krishnaswami, Charles Mebus
OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Throughout tofacitinib clinical studies, a 28-joint Disease Activity Score (DAS28)-based analysis was used to assess outcomes. In this study, remission rates by various remission criteria were evaluated across five Phase 3 randomized controlled studies. METHODS: Tofacitinib was dosed 5 or 10 mg twice daily (BID), either as monotherapy, or with background methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (DMARDs)...
December 1, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27906048/comparative-effectiveness-of-abatacept-versus-tocilizumab-in-rheumatoid-arthritis-patients-with-prior-tnfi-exposure-in-the-us-corrona-registry
#6
Leslie R Harrold, George W Reed, Daniel H Solomon, Jeffrey R Curtis, Mei Liu, Jeffrey D Greenberg, Joel M Kremer
BACKGROUND: We compared the effectiveness of abatacept (ABA) vs tocilizumab (TCA) in tumor necrosis factor inhibitor (TNFi) experienced patients. METHODS: We identified rheumatoid arthritis (RA) patients from a large observational US cohort (1 January 2010-31 May 2014) who had discontinued at least one TNFi and initiated ABA or TCZ in moderate or high disease activity based on the Clinical Disease Activity Index (CDAI) and had no prior exposure to the comparator drug...
December 1, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27903508/the-patient-perspective-on-absence-of-disease-activity-in-rheumatoid-arthritis-a-survey-to-identify-key-domains-of-patient-perceived-remission
#7
Lilian H D van Tuyl, Martina Sadlonova, Sarah Hewlett, Bev Davis, Caroline Flurey, Niti Goel, Laure Gossec, Cecilie Heegaard Brahe, Catherine L Hill, Wijnanda Hoogland, John Kirwan, Merete L Hetland, Dirkjan van Schaardenburg, Josef S Smolen, Tanja Stamm, Marieke Voshaar, George A Wells, Maarten Boers
BACKGROUND: Guidelines suggest treatment in rheumatoid arthritis (RA) to target remission, in close consultation with the patient. Our recent qualitative study of the patients' perspective on remission in RA identified 26 domains. The current study aimed to identify a short list of the most important aspects to inform future research. METHODS: Patients with RA from the Netherlands, the UK, Austria, Denmark, France and the USA completed a survey that contained all domains identified in our qualitative study...
November 30, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27896522/tapering-biologics-in-rheumatoid-arthritis-a-pragmatic-approach-for-clinical-practice
#8
Aleksander Lenert, Petar Lenert
Optimal rheumatoid arthritis (RA) therapy in daily clinical practice is based on the treat-to-target strategy. Quicker escalation of therapy and earlier introduction of biological disease-modifying anti-rheumatic drugs have led to improved outcomes in RA. However, chronic immunosuppressive therapy is associated with adverse events and higher costs. In addition, our patients frequently express a desire for lower dosing and drug holidays. Current clinical practice guidelines from the American College of Rheumatology and European League Against Rheumatism suggest that rheumatologists consider tapering treatment after achieving remission...
November 28, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27894284/proarrhythmic-risk-and-determinants-of-cardiac-autonomic-dysfunction-in-collagen-induced-arthritis-rats
#9
Ting-Tse Lin, Yen-Ling Sung, Chih-En Wu, Hong Zhang, Yen-Bin Liu, Shien-Fong Lin
BACKGROUNDS: Patients with rheumatoid arthritis (RA) have increased risk of sudden cardiac death (SCD), which is two-fold higher than general population. The driving cause of SCD was considered due to lift-threatening arrhythmia where systemic inflammation acts as the pathophysiological basis linking RA to autonomicdysfunction. METHODS: To assess the sympathetic over-activity of "inflammatory reflex", we measured heart rate variability (HRV) in a rat collagen-induced arthritis (CIA) model, whose arthritis is induced in Lewis rats by intradermal injection of emulsion of type II collagen...
November 29, 2016: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/27893771/a-nationwide-survey-on-patient-s-versus-physician%C3%A2-s-evaluation-of-biological-therapy-in-rheumatoid-arthritis-in-relation-to-disease-activity-and-route-of-administration-the-be-raise-study
#10
Sophie De Mits, Jan Lenaerts, Bert Vander Cruyssen, Herman Mielants, René Westhovens, Patrick Durez, Dirk Elewaut
OBJECTIVES: Biological treatment of rheumatoid arthritis (RA) is one of the cornerstones of current treatment strategies for the disease. Surprisingly little information exists on whether the route of administration affects patients' treatment satisfaction. It is equally unclear whether rheumatologists are able to accurately perceive their patients' appreciation. Thus, the Belgian Be-raise survey aimed to examine whether RA patient's experience of their current biological treatment coincided with the treating physician's perception...
2016: PloS One
https://www.readbyqxmd.com/read/27888965/effects-of-nursing-interventions-on-depression-of-patients-with-rheumatoid-arthritis-a-meta-analysis-of-randomized-controlled-trials
#11
Biyun Zhou, Guohong Li, Yuqun Zhang, Zihan Zhao
INTRODUCTION: Previous randomized controlled trials have led to conflicting findings regarding the effects of nursing interventions on depression of patients with rheumatoid arthritis (RA). The purpose of this study was to use the meta-analytic approach to resolve these discrepancies. METHODS: We performed a systematic search of publications using MEDLINE, EMBASE, the Cochrane Library, and manual searches without language restrictions. Studies that met the following criteria were included: (1) randomized controlled trials; (2) duration of intervention≥4 weeks; (3) comparative control group; (4) adults with RA; (5) published studies in any language since reception; and (6) psychological symptoms assessed...
December 2016: Archives of Psychiatric Nursing
https://www.readbyqxmd.com/read/27858176/serum-level-of-reactive-oxygen-metabolites-rom-at-12%C3%A2-weeks-of-treatment-with-biologic-agents-for-rheumatoid-arthritis-is-a-novel-predictor-for-52-week-remission
#12
Arata Nakajima, Yasuchika Aoki, Masato Sonobe, Hiroshi Takahashi, Masahiko Saito, Koichi Nakagawa
We have shown that serum levels of reactive oxygen metabolites (ROM) were associated with C-reactive protein (CRP) and disease activity score based on the examination of 28 joints (DAS28) in patients with rheumatoid arthritis (RA); however, their clinical significance as biomarkers has not been elucidated. Forty-eight biologic agent (BA)-naïve RA patients were included in this study. Associations between serum levels of ROM, CRP, matrix metalloproteinase-3 (MMP-3), DAS28-erythrocyte sedimentation rate (ESR), and Health Assessment Questionnaire (HAQ) at 12 weeks of treatment and DAS28 (ESR) remission at 52 weeks (52-week remission) were investigated...
November 17, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27856656/stopping-tumour-necrosis-factor-targeted-biological-dmards-in-rheumatoid-arthritis
#13
REVIEW
Yoshiya Tanaka
The combined use of MTX and biological DMARDs (bDMARDs) targeting TNF has revolutionized treatment of RA, and clinical remission becomes a realistic treatment goal. After sustained remission, discontinuation of bDMARDs without disease flare has been emerging as an important theme from the risk-benefit point of view and economic burden. According to several studies, approximately half of early RA patients could discontinue TNF-targeted bDMARDs without clinical flare and functional impairment after obtaining low disease activity or remission by treatment with bDMARDs and MTX...
December 2016: Rheumatology
https://www.readbyqxmd.com/read/27856432/efficacy-and-safety-of-sarilumab-monotherapy-versus-adalimumab-monotherapy-for-the-treatment-of-patients-with-active-rheumatoid-arthritis-monarch-a-randomised-double-blind-parallel-group-phase-iii-trial
#14
Gerd R Burmester, Yong Lin, Rahul Patel, Janet van Adelsberg, Erin K Mangan, Neil M H Graham, Hubert van Hoogstraten, Deborah Bauer, Juan Ignacio Vargas, Eun Bong Lee
OBJECTIVES: To compare efficacy and safety of sarilumab monotherapy with adalimumab monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment with methotrexate (MTX) due to intolerance or inadequate response. METHODS: MONARCH was a randomised, active-controlled, double-blind, double-dummy, phase III superiority trial. Patients received sarilumab (200 mg every 2 weeks (q2w)) or adalimumab (40 mg q2w) monotherapy for 24 weeks...
November 17, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27855242/biologic-or-tofacitinib-monotherapy-for-rheumatoid-arthritis-in-people-with-traditional-disease-modifying-anti-rheumatic-drug-dmard-failure-a-cochrane-systematic-review-and-network-meta-analysis-nma
#15
REVIEW
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell, George A Wells
BACKGROUND: We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced). OBJECTIVES: To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced...
November 17, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27846761/prognostic-factors-of-methotrexate-associated-lymphoproliferative-disorders-associated-with-rheumatoid-arthritis-and-plausible-application-of-biological-agents
#16
Takayuki Katsuyama, Ken-Ei Sada, Minglu Yan, Sonia Zeggar, Sumie Hiramatsu, Yoshia Miyawaki, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Eri Katsuyama, Mariko Takano-Narazaki, Noriko Toyota-Tatebe, Katsue Sunahori-Watanabe, Tomoko Kawabata, Kohei Miyake, Toru Kiguchi, Jun Wada
OBJECTIVES: To determine prognostic factors of methotrexate-associated lymphoproliferative disorder (MTX-LPD) and evaluate the efficacy and safety of biological therapy in rheumatoid arthritis (RA) complicated with MTX-LPD. METHODS: Thirty RA patients who developed MTX-LPD were investigated in this study. We compared the clinical and laboratory parameters of patients who achieved regression of LPD by MTX withdrawal with those who required chemotherapy and evaluated the clinical course of RA after LPD development...
November 16, 2016: Modern Rheumatology
https://www.readbyqxmd.com/read/27846756/simplified-disease-activity-index-remission-at-month-6-is-an-independent-predictor-of-functional-and-structural-remissions-at-month-12-during-abatacept-treatment-in-patients-with-rheumatoid-arthritis-a-multi-center-prospective-cohort-study-in-japan
#17
Hayato Yamazaki, Fumio Hirano, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Mari Kihara, Waka Yokoyama, Takahiko Sugihara, Kenji Nagasaka, Hiroyuki Hagiyama, Yoshinori Nonomura, Ryoko Sakai, Michi Tanaka, Ryuji Koike, Toshihiro Nanki, Hitoshi Kohsaka, Nobuyuki Miyasaka, Masayoshi Harigai
OBJECTIVE: To evaluate association of clinical remission at month 6 with functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis (RA). METHODS: This 12-month prospective, multicenter cohort study enrolled 168 patients with RA who started abatacept. Outcomes were assessed using composite measures, quality of life indices, and the van der Heijde-modified total Sharp score (mTSS). The logistic regression analysis was applied to identify factors associated with outcomes and their odds ratios (OR) with 95% confidence interval (95% CI)...
November 16, 2016: Modern Rheumatology
https://www.readbyqxmd.com/read/27843372/wissler-fanconi-syndrome-and-related-diagnoses-a-case-report
#18
Mustafa Q Albustani, Robert F Howard
INTRODUCTION: Wissler-Fanconi syndrome is a rare rheumatic syndrome that was first described during the 1940s in Europe. Since then, many papers have been written that cover all aspects of this syndrome, most of which are in French and German language, with only a very few in English (none of them recent). We report here a case that fulfils the criteria for Wissler-Fanconi syndrome. Under the more general descriptive umbrella of Wissler-Fanconi syndrome, our patient also fulfils the Modified Jones criteria, and the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for rheumatoid arthritis, and was interpreted by other internists and another rheumatologist as fulfilling the Yamaguchi criteria for adult onset Still's disease...
2016: Open Access Rheumatol
https://www.readbyqxmd.com/read/27843370/rheumatoid-arthritis-in-patients-with-hiv-management-challenges
#19
REVIEW
Matthew B Carroll, Joshua H Fields, Philip G Clerc
Over the past few decades, HIV has been transformed from a once-uniformly fatal disease to now a manageable but complex multisystem illness. Before highly active antiretroviral therapy (HAART), reports suggested that HIV-infected patients with rheumatoid arthritis (RA) would experience remission of their disease. It has now become clear that RA can develop in HIV-infected patients at any time, independent of HAART. Choosing the right medication to treat symptoms related to RA while avoiding excess weakening of the immune system remains a clinical challenge...
2016: Open Access Rheumatology: Research and Reviews
https://www.readbyqxmd.com/read/27843369/polymyalgia-rheumatica-observations-of-disease-evolution-without-corticosteroid-treatment
#20
Arthur E Brawer
OBJECTIVES: The diagnostic diversity of polymyalgia rheumatica (PMR) can easily be obscured by the widespread use of corticosteroids (CSs) early in the disease course. This study observed the course of PMR without CSs and determined whether alternative medication could be useful. METHODS: Seventy patients with new-onset PMR comprised phase 1. Eight were removed with specific diagnoses (four with giant cell arteritis [GCA]). The remaining 62 were treated with nonsteroidal anti-inflammatory drugs (NSAIDs) alone until enough time had elapsed to ascertain whether their PMR had evolved into another rheumatologic inflammatory condition...
2016: Open Access Rheumatology: Research and Reviews
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"